null

VivoGenie Anti-VEGF (Bevacizumab) Biosimilar (IVMB0232)

SKU:
IVMB0232
Antibody Type:
In Vivo Biosimilar
Endotoxin Level:
Low Endotoxin
Applications:
In Vivo
Disease Area:
Angiogenesis
Disease Area:
Cancer
Disease Area:
Ocular Disorders
Protein:
VEGF
Clone:
A4.6.1
Isotype:
IgG1 kappa
Reactivity:
Human
Synonyms:
Vascular Endothelial Growth Factor, VEGF-A, VEGFA, Vascular Permeability Factor, VPF
€269 - €7,279

Description

system_update_altDatasheet
Product Name:Bevacizumab (Anti-VEGF) Biosimilar In Vivo Antibody
Product Code:IVMB0232
Clone:A4.6.1
Protein:VEGF
Product Type:Biosimilar Recombinant Human Monoclonal Antibody
Synonyms:Vascular Endothelial Growth Factor, VEGF-A, VEGFA, Vascular Permeability Factor, VPF
Isotype:Human IgG1κ
Reactivity:Human
Immunogen:Recombinant human VEGF.
Applications:B, ELISA, FC, IP, N, WB
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:B, ELISA, FC, IP, N, WB
Recommended Usage:FC
The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 106 in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
WB
ELISA
Reactivity:Human
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only.
Antigen Distribution:VEGF is widely expressed in the thyroid, prostate, and various other tissues.
Immunogen:Recombinant human VEGF.
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.
Protein:VEGF

Related Products